• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    KKR’s Medtech Push With Allyntra Might Change The Case For Investing In KKR (KKR)

    Simply Wall St·07/17/2026 21:24:23
    Listen to the news
    • In early July 2026, KKR launched Allyntra, a precision-engineered solutions platform built around its existing Precipart investment to serve advanced medical technology and other high-specification end markets, while also emerging as a potential bidder in early-stage takeover discussions for Qiagen and reportedly considering options for its Arnott’s stake.
    • By pairing fresh capital commitments and seasoned medtech manufacturing leadership at Allyntra with active portfolio reshaping and new partnerships such as the Thomson Reuters Global Print joint venture, KKR is signaling a broader push to refine how and where it deploys capital across healthcare, consumer and information-services assets.
    • Next, we’ll examine how KKR’s creation of Allyntra in precision medtech could influence its long-term investment narrative and growth profile.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

    KKR Investment Narrative Recap

    To own KKR, you have to believe in its ability to keep scaling fee-based alternatives and private credit while managing asset quality, liquidity and fundraising competition. Recent headlines around Allyntra, possible Qiagen interest and a potential Arnott’s exit do not obviously change the near term focus on credit performance and fundraising momentum, but they do highlight execution and valuation risks around capital deployment and realizations.

    Among the latest updates, the launch of Allyntra looks most relevant here. It extends KKR’s healthcare footprint into precision medtech manufacturing at a time when fee based, less cyclical platforms are central to many investors’ catalysts. How Allyntra is built out, and how any Qiagen or Arnott’s transactions are structured, could influence the balance between stable fee income and more volatile performance revenues in the quarters ahead.

    Yet while investors may be drawn to KKR’s growth platforms, they should not ignore the possibility that concentrated credit and valuation risks could...

    Read the full narrative on KKR (it's free!)

    KKR's narrative projects $13.7 billion revenue and $5.4 billion earnings by 2028. This requires a 13.9% yearly revenue decline and an earnings increase of about $3.4 billion from $2.0 billion today.

    Uncover how KKR's forecasts yield a $140.24 fair value, a 39% upside to its current price.

    Exploring Other Perspectives

    KKR 1-Year Stock Price Chart
    KKR 1-Year Stock Price Chart

    Compared with the baseline optimism around fundraising and credit scale, the most bearish analysts were already assuming KKR’s revenue could fall about 21 percent a year even as earnings climbed toward roughly US$6.0 billion, reminding you that views on how ventures like Allyntra or a potential Qiagen deal might play out can differ sharply and may need revisiting as this news settles.

    Explore 8 other fair value estimates on KKR - why the stock might be worth as much as 49% more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your KKR research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free KKR research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate KKR's overall financial health at a glance.

    Searching For A Fresh Perspective?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.